A repurposed cancer drug has been shown to be 100% effective in treating malaria in a Phase 2 clinical trial. Purdue University professor Philip Low led the international team that made the discovery.
(Purdue University photo/John Underwood)
A cancer drug repurposed to treat malaria has been shown to be nearly 100% effective in helping defeat the disease in just three days, according to the results of a Phase 2 clinical trial.
The results of the trial were published Thursday (Aug. 26) in the Journal of Experimental Medicine.
The trial shows that the addition of the drug Imatinib to the customary malaria therapy enables clearance of all malaria parasites from 90% of patients within 48 hours and from 100% of patients within three days, says Philip Low, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, who co-directed the international research team. The patients receiving Imatinib also were relieved of their fevers in less than half of the time experienced by similar patients treated with the standard therapy.
“In our trial, 33% of the patients treated with the standard therapy (but without the Imatinib supplement) still suffered from significant parasitemia after three days,” said Low (rhymes with “now”). “Delayed clearance rates are a precursor to and an indicator of potential drug resistance, which has been a problem with malaria for decades. So, this could be significant.”
Imatinib was originally produced by Novartis for the treatment of chronic myelogenous leukemia and other cancers. It works by blocking specific enzymes involved in the growth of cancers.
“When we discovered the ability of Imatinib to block parasite propagation in human blood cultures in petri dishes, we initiated a human clinical trial where we combined Imatinib with the standard treatment (piperaquine plus dihydroartemisinin) used to treat malaria in much of the world,” Low said. “The Phase 2 clinical trial that is described in the paper in Journal of Experimental Medicine compares the standard treatment with Imatinib plus the standard treatment. We did not test Imatinib alone, because it would have been unethical to treat patients suffering from a potentially lethal disease with an untested therapy.”
Malaria infects human red blood cells, where it reproduces and eventually activates a red blood cell enzyme that, in turn, triggers rupture of the cell and release of a form of the parasite called a merozoite into the bloodstream. Low and his colleagues theorized that by blocking the critical red blood cell enzyme, they could stop the infection. The data from the drug trial confirms that.
Low said for the past 50 years, malaria treatments have used drugs that target the parasite itself, but the microorganism eventually developed resistance to the drugs.
“Because we’re targeting an enzyme that belongs to the red blood cell, the parasite can’t mutate to develop resistance — it simply can’t mutate proteins in our blood cells,” Low said. “This is a novel approach that will hopefully become a therapy that can’t be evaded by the parasite in the future. This would constitute an important contribution to human health.”
Malaria is caused by a single-cell parasite, Plasmodium, which is carried by mosquitoes. The World Health Organization estimates that the disease caused 409,000 deaths in 2019 (the most recent year for which data is available). The WHO also notes that 67% of those deaths were in children under 5 years old.
The deadliest form of the parasite is P. falciparum, and although most malaria deaths occur in sub-Saharan Africa, a variant of P. falciparum that is developing drug resistance has become established in a corner of Southeast Asia, particularly in Cambodia, Myanmar, Thailand, Laos and Vietnam. In some regions of the area, up to 80% of malaria parasites are at least partially drug resistant.
In 2019, professor Olivo Miotto from the Wellcome Sanger Institute of the University of Oxford, told the BBC the rise of the drug-resistant variant in Southeast Asia raises the “terrifying prospect” of the drug-resistant variety traveling to Africa. A similar event occurred in the 1980s with malaria resistant to the then-standard treatment of chloroquine, which resulted in millions of deaths.
Low and his colleagues tested Imatinib in a hot zone of drug-resistant malaria on the border of Vietnam and Laos, in the Quang Tri Province of Vietnam.
“It’s such a remote region of the country that most of the clinics are one- or two-room cinder block buildings with just six or seven cots where people can come in and get treated,” Low said. “Not only was the drug 100% effective after three days, but the patients saw their fever disappear on the first day, and they felt much better sooner.”
Although malaria is not a significant disease in North America, Low is planning to apply for approval by the U.S. Food and Drug Administration.
“The FDA is so widely respected around the world that if they approve it, almost all other nations, especially developing countries that suffer from malaria, will rapidly adopt it,” he said. “The FDA requirements for Phase 3 approval are very rigorous. You have to demonstrate the drug combination’s efficacy and safety in a large patient population and then show that you can manufacture and store it safely and reproducibly. You also have to start from scratch and end up with a product that is more than 99% pure.”
Low said he has been in discussions with drug manufacturers in India and Vietnam to produce the drug and estimates that can be done for roughly $1 per pill.
“We’ll turn over the technology to any company committed to distributing it to developing malaria-infested areas,” he said. “I’m not interested in making a penny off of this. I just think it’s important for humanity to have it.”
Original Article: Malaria treatment shown to be 100% effective in Phase 2 trial
More from: Purdue University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Imatinib and malaria
- UVM study links deforestation with higher risk of childhood malaria
Malaria kills more than 600,000 people each year worldwide, and two thirds are children under age five in sub-Saharan Africa.
- Malaria in Pregnancy
Despite increased malaria control efforts, recent reports indicate that over 1.2 million deaths due to malaria occurred in 2010. Pregnant women represent a particularly vulnerable risk group as ...
- Ancient Humans May Have Built a Resistance to Malaria
A mosquito-borne parasite, Plasmodium malariae causes malaria - a disease responsible for at least 608,000 deaths and 249 million cases in 2022, according to the World Health Organization. Malaria ...
- The journey with malaria so far
Malaria is a disease condition that we had cause to deal with on this page in 2013 in a two-part essay. We return to the topic today not because there are no other diseases to discuss, but because ...
- Second malaria vaccine highly protective, trial results show
LONDON, Feb 1 (Reuters) - A malaria vaccine developed by the University of Oxford and the Serum Institute of India prevented around three-quarters of symptomatic malaria cases in young children ...
Go deeper with Google Headlines on:
Imatinib and malaria
[google_news title=”” keyword=”Imatinib and malaria” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- UG's Dr. Richard Amewu leads major project to accelerate malaria drug discoveryon March 4, 2024 at 9:19 am
Under the Grand Challenges Africa Drug Discovery Accelerator (GC ADDA) programme, Dr. Richard Amewu, a Senior Lecturer at the Department of Chemistry and Head of the Drug Innovations Group at the ...
- Kent Campbell - Trailblazer in Fight to End Malaria (1944-2024)on March 4, 2024 at 3:47 am
Carlos 'Kent' Campbell, a respected public health physician and global health champion who died on February 20, 2024, is being celebrated by colleagues and coworkers for his pivotal role in fight to ...
- NASA satellites revolutionize malaria prevention by forecasting outbreaks in Amazonon March 3, 2024 at 10:57 am
NASA satellites have emerged as a vital tool in the fight against malaria outbreaks in the Amazon Rainforest, where the disease poses a significant threat to people living in that region. University ...
- Second malaria vaccine highly protective, trial results showon March 2, 2024 at 8:31 pm
LONDON, Feb 1 (Reuters) - A malaria vaccine developed by the University of Oxford and the Serum Institute of India prevented around three-quarters of symptomatic malaria cases in young children the ...
- Soldiers harmed by anti-malaria drug launch landmark legal claim against MoDon March 2, 2024 at 7:00 am
Veterans and military personnel who suffered debilitating side-effects from the controversial anti-malarial drug Lariam have launched a groundbreaking legal battle against the Ministry of Defence. Ten ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”malaria” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]